QIAGEN powered by

Clinical
Events
Monday, February 22, 2016

Scalable NGS-based test interpretation in oncology

We were honored to take part in last month’s Personalized Medicine World Conference (PMWC), where speakers and attendees focused on critical areas such as liquid biopsies, pathology, immuno-oncology, next-generation sequencing, and more.

Sean Scott, VP, New Ventures here at QIAGEN Bioinformatics, presented a talk on “Enabling precision medicine in oncology through scalable NGS-based test interpretation and actionable reporting.” Sean has presented at the PWMC event for the past four years and this event continues to grow in importance. If you couldn’t make it to the event, here’s a quick recap of his presentation.

Sean reviewed current trends and shifts in NGS-based testing of cancer patients, noting the significant improvement in our ability to treat this disease by using genomic information. He walked through some of the challenges facing clinical testing labs, such as scientific and technical complexity of NGS tests, the operational scale challenges with NGS tests, the opportunity for labs to differentiate their test offerings through bioinformatics and data aggregation, as well as continued uncertainty in reimbursement hurdles.

Sean showcased the value of the QIAGEN Clinical Insight platform in enabling clinical labs in scaling their test analysis, interpretation and reporting in both somatic and inherited/germline cancers. He also presented on QIAGEN’s strategy for de-identified genomic data and progress with the Allele Frequency Community, an opt-in community co-founded by QIAGEN Bioinformatics that allows labs to share allele frequency statistics for the benefit of patients and clinical research, and the INOVA Compendium.

As always, the PMWC event was an excellent event. If you couldn’t make it this year, we hope to see you there next year!

More information

Learn more about QIAGEN Clinical Insight